News @ Qprotyn

Changing the world, one mAb at a time.

We are always pushing the frontier of technology’s impact in the world of biologics. We feel that modern technology allows easy crossover of ideas across borders and cultures. Our achievements and our knowledge are to be shared with the community and the technology ecosystem.

Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO® technology.

Janak Vadgama

Sep 3, 2021
2 min

Qprotyn achieves viscosity of 18cP for 250mg/mL of Trastuzumab using its HILOPRO® technology.

Upgrading Trastuzumab from IV to Subcutaneous (SubQ) administration may now be possible without expensive, high-volume hyaluronidase injections. With HILOPRO technology Without viscosity-reducing excipients Due to patients’ convenience of at-home administration and reduced number of hospital visits as well as the reduction in treatment costs, SubQ administration of biologics is of increasing interest. Trastuzumab targets Human IgG1/TNFα and is approved for breast cancer, gast

89 views

Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO® technology.

Janak Vadgama

Aug 5, 2021
2 min

Qprotyn achieves viscosity of 14 cP for 250mg/mL of Bevacizumab using its HILOPRO® technology.

Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology Innovator Bevacizumab was first sold under the brand name Avastin(R) by Genentech - a member of the Roche Group. First approved in the United States in 2004 and in the European Union in 2005, Bevacizumab is now used to treat different types of cancers and age-related macular degeneration (AMD) particularly for the choroidal neovascular membrane in AMD. To

35 views